WASHINGTON — A possible Trump administration effort to change the childhood vaccine schedule left hospital leaders, health policymakers, and pediatricians scrambling to navigate what could be the most significant changes to the American vaccine program in decades. The administration had planned to announce on Friday moves to pare down the number of shots on the…
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. This is our last newsletter of the year! We’re taking a break but we’ll be back on Monday, Jan. 5. In the meantime, hope you all enjoy the holidays, eat lots, and sleep…
Bob Herman covers health insurance, government programs, hospitals, physicians, and other providers — reporting on how money influences those businesses and shapes what we all pay for care. He is also the author of the Health Care Inc. newsletter. You can reach Bob on Signal at bobjherman.09. This is the online version of STAT’s weekly…
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Morning, all! Today, we hear an optimistic view of the biotech IPO market next year, note a few key FDA issues to watch in 2026, see an interesting Trump deal that asks companies to…
Good morning, Jason Mast here filing in for Ed on this Christmas week. No coffee this morning — well, not yet — but rather some Yemeni Tea from a certain rapidly expanding New York haunt. It’s sweeter than my usual cup and warmer. Ten out of ten. Anyway, here’s some news for you today. I…
WASHINGTON — The Food and Drug Administration is in a precarious position as it heads toward 2026. The agency has been mired by high-profile departures, feuds between top leaders, accusations of politicization, and low morale. It has lost thousands of employees to layoffs and resignations and cannot seem to hold onto a director of the…
For BioMarin CEO Alexander Hardy, this morning’s purchase of Amicus Therapeutics for $4.8 billion represents a long-awaited major bet — and one Wall Street has been waiting for. Hardy, previously CEO of Roche’s Genentech unit, took over for longtime BioMarin CEO Jean Jacques Biename. Since his appointment was announced, BioMarin shares have fallen by more…
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Morning. Today, we exclusively write about how politics are shaping the new FDA voucher program, see how the U.K. might buoy U.S. science with renewed investment, and more. The need-to-know this morning BioMarin said…
In July 2006, The New York Times sent young reporter Alex Berenson to Pfizer to interview me about the company’s future R&D prospects. Given its large R&D budget, it was natural to use Pfizer as a barometer of the pharmaceutical industry, which was in the midst of a productivity slump. In the 1990s, the Food…
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Happy Thursday. Today, we report on expectations President Trump will unveil more pricing deals with pharma, see new FDA labeling that could affect Pfizer in court, and more. The need-to-know this morning Takeda said its…